AGM/EGMMay 27, 2026, 05:01 PM
Dermata Stockholders Approve Equity Plan Share Increase, Warrant Actions
AI Summary
Dermata Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders where several key proposals were approved. Shareholders elected three Class II directors and ratified CBIZ CPAs P.C. as the independent auditor. Crucially, stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing available shares to 402,214. Additionally, proposals for the issuance of shares underlying certain warrants and the repricing of warrants for up to 120,734 shares were also approved, along with an adjournment proposal.
Key Highlights
- Shareholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing shares to 402,214.
- Approval was granted for the issuance of shares underlying certain warrants, complying with Nasdaq Listing Rule 5635(d).
- Warrant repricing for up to 120,734 shares of Common Stock was approved.
- David Hale, Steven Mento, Ph.D., and Brittany Bradrick were elected as Class II directors.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for 2026.
- Approximately 59% of outstanding common shares were represented at the Annual Meeting.
Price Impact
More from DRMA